Program 2, the Molecular Biology and Genetics of Cancer Program (MBG), integrates fundamental studies in the control of gene transcription and regulation with the genetic and molecular mechanisms underlying the most common types of solid tumors and hematological malignancies. An integral part of the KCC since 1991, this program focuses on gene discovery and gene function analyses in order to exploit the translational potential of these studies for cancer diagnosis, assessment, prevention and therapy. The long-term goal of this program is to discover information useful in designing """"""""personalized therapies"""""""" for cancer patients. The Molecular Biology and Genetics of Cancer Program brings together 22 faculty members from 10 academic departments (including the Lankenau Institute for Medical Research and the Department of Biochemistry and Molecular Biology of Drexel University) who are supported by NCI ($3.25 million total costs) and other peer-reviewed grants ($7.80 million total costs). Many members of this program have made important discoveries that have been translated into improved cancer diagnosis and assessment, and into novel therapeutic approaches. In the last five years, program members have continued to interact productively, publishing approximately 100 papers/year in some of the best known and more influential journals such as Nature, Mol.Cell, J.Clin.Invest., Immunity, PNAS. Of papers published since 2007, 21.0% have been the result of intra-programmatic collaborations and 31.3% the result of inter-programmatic collaborations. The program has 15-20 graduate students and more than 80 postdoctoral fellows. Their training and the interactions, both intra- and inter-programmatic, among all members are supported by monthly meetings that enhance the program's translational focus.

Public Health Relevance

Since 1991, the members of Molecular Biology and Genetics of Cancer Program of the Kimmel Cancer Center investigate mechanisms of cell growth and proliferation in normal cells and how these are altered in tumors. Members of this program have made important discoveries useful in cancer diagnosis, assessment, and therapy. The long-term goal of this program is to discover information that can be useful in designing personalized therapies for cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA056036-15
Application #
8753662
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
2014-06-01
Project End
2018-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Type
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603
Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38:
Waldman, Scott A; Camilleri, Michael (2018) Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 67:1543-1552

Showing the most recent 10 out of 807 publications